SAUDI INDUSTRIAL INVESTMENT GROUP COMPANY
(A Saudi Joint Stock Company)

CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (UNAUDITED)
FOR THE THREE-MONTH AND NINE-MONTH PERIODS ENDED 30 SEPTEMBER 2025
AND REPORT ON REVIEW OF CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

SAUDI INDUSTRIAL INVESTMENT GROUP COMPANY
(A Saudi Joint Stock Company)
CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (UNAUDITED)
FOR THE THREE-MONTH AND NINE-MONTH PERIODS ENDED 30 SEPTEMBER 2025

Report on review of condensed consolidated interim financial statements

To the shareholders of Saudi Industrial Investment Group Company
(A Saudi Joint Stock Company)

Introduction

We have reviewed the accompanying condensed consolidated interim statement of financial position of Saudi Industrial Investment Group Company (the “Company”) and its subsidiaries (together the “Group”) as of 30 September 2025 and the related condensed consolidated interim statement of profit or loss and other comprehensive income for the three-month and nine-month periods then ended and the condensed consolidated interim statements of changes in equity and cash flows for the nine-month period then ended and other explanatory notes. Management is responsible for the preparation and presentation of these condensed consolidated interim financial statements in accordance with International Accounting Standard 34 - “Interim Financial Reporting” (IAS 34), as endorsed in the Kingdom of Saudi Arabia. Our responsibility is to express a conclusion on these condensed consolidated interim financial statements based on our review.

Scope of review

We conducted our review in accordance with International Standard on Review Engagements 2410, “Review of interim financial information performed by the independent auditor of the entity”, as endorsed in the Kingdom of Saudi Arabia. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with International Standards on Auditing, as endorsed in the Kingdom of Saudi Arabia, and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Conclusion

Based on our review, nothing has come to our attention that causes us to believe that the accompanying condensed consolidated interim financial statements are not prepared, in all material respects, in accordance with IAS 34, as endorsed in the Kingdom of Saudi Arabia.

PricewaterhouseCoopers

Sahar Hashem
License Number 439

برايس وترهاوس كوبرز
محاسبون قانونيون
ترخيص ٣٢٣/١١/٢٥/٢
س.ت ٢٠٥١٠٦٢٣٨٤
PRICEWATERHOUSECOOPERS
CERTIFIED PUBLIC ACCOUNTS
Lic No. 323/11/25/2
C.R. 2051062384

28 October 2025

Branch of PricewaterhouseCoopers Public Accountants (Professional Limited Liability Company),UN No. 7003482499, CR No. 2051062384 (Main CR No. 1010371622,main UN No. 7000928734), Capital SR 500,000, National Address: 5374 King Salman Bin Abdulaziz Road, Al Hizam Al Akhdar District, Postal Code 34433, Secondary No. 6676, Al Khobar, Kingdom of Saudi Arabia, physical address: Al Hugayet Tower floor 15
T: +966 (13) 849-6311, F: +966 (13) 849-6281

SAUDI INDUSTRIAL INVESTMENT GROUP COMPANY
(A Saudi Joint Stock Company)
Condensed consolidated interim statement of financial position
(All amounts in Saudi Riyals thousands unless otherwise stated)

	Note	As at 30 September 2025 (Unaudited)	As at 31 December 2024 (Audited)
Assets			
Non-current assets			
Property and equipment	6	**25,544**	1,772
Investments accounted for using the equity method	7	**8,175,154**	8,329,969
Other assets		**8,085**	6,405
Total non-current assets		**8,208,783**	8,338,146
Current assets			
Prepayments and other current assets		**7,928**	8,505
Due from related parties	8	**634,952**	805,577
Short-term murabaha deposits		**-**	30,152
Cash and cash equivalents	9	**308,017**	919,068
Total current assets		**950,897**	1,763,302
Total assets		**9,159,680**	10,101,448
Equity and liabilities			
Equity			
Share capital	10	**6,793,200**	7,548,000
Share premium		**7,970,520**	7,970,520
Acquisition reserve		**(6,349,090)**	(6,349,090)
Treasury shares	11	**(200,117)**	-
Retained earnings		**711,280**	665,087
Equity attributable to the shareholders of the Company		**8,925,793**	9,834,517
Non-controlling interest	1	**6,525**	-
Net equity		**8,932,318**	9,834,517
Liabilities			
Non-current liabilities			
Employee benefit obligations		**30,732**	28,499
Current liabilities			
Accrued and other liabilities		**36,728**	43,125
Due to related parties	8	**5,751**	-
Zakat provision	12	**154,151**	195,307
Total current liabilities		**196,630**	238,432
Total liabilities		**227,362**	266,931
Total equity and liabilities		**9,159,680**	10,101,448

The accompanying notes are an integral part of these condensed consolidated interim financial statements.

Khalil Al-Watban	Abdulrahman S. Alismail	Husam Albader
Chairman - Board of Directors	CEO	CFO

SAUDI INDUSTRIAL INVESTMENT GROUP COMPANY
(A Saudi Joint Stock Company)
Condensed consolidated interim statement of profit or loss and other comprehensive income
(All amounts in Saudi Riyals thousands unless otherwise stated)

	Note	For the three-month period ended 30 September 2025 (Unaudited)	For the three-month period ended 30 September 2024 (Unaudited)	For the nine-month period ended 30 September 2025 (Unaudited)	For the nine-month period ended 30 September 2024 (Unaudited)
Share of net profit of investments accounted for using the equity method	7	**24,313**	126,327	**87,390**	250,841
General and administrative expenses		**(17,193)**	(20,091)	**(47,496)**	(47,088)
Operating profit		**7,120**	106,236	**39,894**	203,753
Finance income from short-term murabaha deposits		**2,054**	5,331	**21,256**	19,742
Profit before zakat		**9,174**	111,567	**61,150**	223,495
Zakat expense	12	**(841)**	(13,481)	**(14,957)**	(33,510)
Profit for the period		**8,333**	98,086	**46,193**	189,985
Other comprehensive income for the period		**-**	-	**-**	-
Total comprehensive income for the period		**8,333**	98,086	**46,193**	189,985
Profit for the period is attributable to:					
Shareholders of Saudi Industrial Investment Group Company		**8,333**	98,086	**46,193**	189,985
Non-controlling interest		**-**	-	**-**	-
		8,333	98,086	**46,193**	189,985
Total comprehensive income for the period is attributable to:					
Shareholders of Saudi Industrial Investment Group Company		**8,333**	98,086	**46,193**	189,985
Non-controlling interest		**-**	-	**-**	-
		8,333	98,086	**46,193**	189,985
Earnings per share (Saudi Riyals)					
Basic and diluted	14	**0.01**	0.13	**0.06**	0.25

The accompanying notes are an integral part of these condensed consolidated interim financial statements.

Khalil Al-Watban	Abdulrahman S. Alismail	Husam Albader
Chairman - Board of Directors	CEO	CFO

SAUDI INDUSTRIAL INVESTMENT GROUP COMPANY
(A Saudi Joint Stock Company)
Condensed consolidated interim statement of changes in equity
(All amounts in Saudi Riyals thousands unless otherwise stated)

	Attributable to the shareholders of Saudi Industrial Investment Group Company							
	Share capital	**Share premium**	**Acquisition reserve**	**Treasury shares**	**Retained earnings**	**Total**	**Non-controlling interest**	**Net equity**
At 1 January 2024 (Audited)	7,548,000	7,970,520	(6,349,090)	-	853,134	10,022,564	-	10,022,564
Profit for the period	-	-	-	-	189,985	189,985	-	189,985
Other comprehensive income for the period	-	-	-	-	-	-	-	-
Total comprehensive income for the period	-	-	-	-	189,985	189,985	-	189,985
Transactions with shareholders in their capacity as shareholders:								
Dividends	-	-	-	-	(377,400)	(377,400)	-	(377,400)
At 30 September 2024 (Unaudited)	7,548,000	7,970,520	(6,349,090)	-	665,719	9,835,149	-	9,835,149

(Continued)

The accompanying notes are an integral part of these condensed consolidated interim financial statements.

Khalil Al-Watban
Chairman - Board of Directors

Abdulrahman S. Alismail
CEO

Husam Albader
CFO

SAUDI INDUSTRIAL INVESTMENT GROUP COMPANY
(A Saudi Joint Stock Company)
Condensed consolidated interim statement of changes in equity
(All amounts in Saudi Riyals thousands unless otherwise stated)

		Attributable to the shareholders of Saudi Industrial Investment Group Company							
	Note	Share capital	Share premium	Acquisition reserve	Treasury shares	Retained earnings	Total	Non-controlling interest	Net equity
At 1 January 2025 (Audited)		7,548,000	7,970,520	(6,349,090)	-	665,087	9,834,517	-	9,834,517
Profit for the period		-	-	-	-	46,193	46,193	-	46,193
Other comprehensive income for the period		-	-	-	-	-	-	-	-
Total comprehensive income for the period		-	-	-	-	46,193	46,193	-	46,193
Transactions with shareholders in their capacity as shareholders:									
Non-controlling interest on incorporation of subsidiary	1	-	-	-	-	-	-	6,525	6,525
Reduction of share capital	10	(754,800)	-	-	-	-	(754,800)	-	(754,800)
Acquisition of treasury shares	11	-	-	-	(200,117)	-	(200,117)	-	(200,117)
At 30 September 2025 (Unaudited)		6,793,200	7,970,520	(6,349,090)	(200,117)	711,280	8,925,793	6,525	8,932,318

The accompanying notes are an integral part of these condensed consolidated interim financial statements.

Khalil Al-Watban Chairman - Board of Directors	Abdulrahman S. Alismail CEO	Husam Albader CFO

SAUDI INDUSTRIAL INVESTMENT GROUP COMPANY
(A Saudi Joint Stock Company)
Condensed consolidated interim statement of cash flows
(All amounts in Saudi Riyals thousands unless otherwise stated)

	Note	For the nine-month period ended 30 September 2025 (Unaudited)	For the nine-month period ended 30 September 2024 (Unaudited)
Cash flows from operating activities			
Profit before zakat		**61,150**	223,495
Adjustments for:			
Depreciation	6	**565**	486
Share of net profit of investments accounted for using the equity method	7	**(87,390)**	(250,841)
Finance income from murabaha deposits		**(21,256)**	(19,742)
Provision for employee benefit obligations		**2,331**	2,524
Changes in operating assets and liabilities:			
Increase in prepayments and other current assets		**(1,103)**	(2,261)
Decrease in accrued and other liabilities		**(6,351)**	(14,279)
Increase in due to related parties		**5,751**	3,915
Cash utilised in operations		**(46,303)**	(56,703)
Finance income from murabaha deposits received		**21,256**	19,742
Zakat paid	12.1	**(56,113)**	(44,236)
Employee benefit obligations paid		**(98)**	(14)
Dividends received from joint ventures	7.1	**268,125**	408,750
Zakat reimbursed to joint ventures	7.1	**(25,920)**	(9,395)
Net cash inflow from operating activities		**160,947**	318,144
Cash flows from investing activities			
Payments for purchase of property and equipment		**(24,337)**	(65)
Proceeds from maturities of short-term murabaha deposits		**30,152**	251,032
Placements of short-term murabaha deposits		**-**	(40,416)
Proceeds from a related party	8	**170,625**	97,500
Net cash inflow from investing activities		**176,440**	308,051
Cash flows from financing activities			
Payment for reduction of share capital	10	**(754,800)**	-
Payment for acquisition of treasury shares	11	**(200,117)**	-
Dividends paid		**(46)**	(747,029)
Proceeds from non-controlling interest in subsidiary	1	**6,525**	-
Net cash outflow from financing activities		**(948,438)**	(747,029)
Net change in cash and cash equivalents		**(611,051)**	(120,834)
Cash and cash equivalents at beginning of the period		**919,068**	575,780
Cash and cash equivalents at end of the period	9	**308,017**	454,946

The accompanying notes are an integral part of these condensed consolidated interim financial statements.

Khalil Al-Watban	Abdulrahman S. Alismail	Husam Albader
Chairman - Board of Directors	CEO	CFO

(All amounts in Saudi Riyals thousands unless otherwise stated)

1 General information

Saudi Industrial Investment Group Company (the "Company") is a Saudi Joint Stock Company registered in Riyadh, Kingdom of Saudi Arabia under Commercial Registration ("CR") number 1010139946 dated on 10 Shaban 1416 H (corresponding to 1 January 1996). The registered address of the Company is P.O. Box 99833, Riyadh, Kingdom of Saudi Arabia.

The accompanying condensed consolidated interim financial statements include the activities of the Company and its following subsidiaries (together the "Group"):

	Country of incorporation	**Effective ownership percentage at**	
		30 September 2025	**31 December 2024**
National Petrochemical Company ("Petrochem")	Kingdom of Saudi Arabia	**100%**	100%
Bioprotein Company ("Bioprotein")	Kingdom of Saudi Arabia	**80%**	-

The Company is principally engaged in investing the funds of its subsidiaries and the management of its subsidiaries.

Petrochem is a Saudi closed joint stock company registered under CR number 1010246363 issued in Riyadh on 8 Rabi Al Awwal 1429 H (corresponding to 16 March 2008), and it was established pursuant to the Ministry of Commerce's resolution number 53/Q dated 16 Safar 1429 H (corresponding to 23 February 2008).

Bioprotein is a Saudi limited liability company registered under CR number 7050869721 issued in Jubail Industrial City on 28 Muharram 1447 H (corresponding to 23 July 2025), and it was established pursuant to the Ministry of Commerce's resolution number 760328 dated 22 Muharram 1447 H (corresponding to 17 July 2025).

Investment in Bioprotein Company

During the period ended 30 September 2025, the Group and Unibio KSA Aps, a wholly owned subsidiary of Unibio, established a new Company named Bioprotein Company, incorporated in the Kingdom of Saudi Arabia. The Group subscribed to 80% of the share capital of Bioprotein Company upon incorporation.

The new Company was formed with an initial share capital of Saudi Riyals 32.6 million, of which the Group contributed Saudi Riyals 26.1 million in proportion to its ownership interest. The purpose of the incorporation is to engage in the preparation, milling and pressing of animal feed; manufacture of non-medicinal feed additives; manufacture of pet feeds; production of various types of proteins; and packaging of animal feeds.

The initial financial position of Bioprotein at the date of incorporation was as follows:

	As at the date of incorporation
Cash and cash equivalents	32,625
Share capital	(32,625)
	-

1 General information (continued)

Investment in Bioprotein Company (continued)

As Bioprotein was newly incorporated and did not constitute a business as defined under IFRS 3 - Business Combinations, the transaction has not been accounted for as a business combination. Accordingly, no goodwill or bargain purchase has been recognised.

The Group has consolidated the financial position of Bioprotein from the date of incorporation, recognising non-controlling interest of 20% in the condensed consolidated interim financial statements for the three-month and nine-month periods ended 30 September 2025.

The condensed consolidated interim financial statements including notes and other explanatory information were approved and authorised for issuance by the Company's Board of Directors on 28 October 2025.

2 Material accounting policy information

The material accounting policy information applied in the preparation of the condensed consolidated interim financial statements of the Group are consistent with those of the previous financial year and corresponding interim reporting periods, except for the adoption of new and amended standards as set out in Note 2.1 (d).

2.1 Basis of preparation

(a) Statement of compliance

These condensed consolidated interim financial statements of the Group have been prepared in compliance with IAS 34 "Interim Financial Reporting" ("IAS 34"), as endorsed in the Kingdom of Saudi Arabia.

The condensed consolidated interim financial statements do not include all the information and disclosures required in the annual consolidated financial statements. Accordingly, these condensed consolidated interim financial statements are to be read in conjunction with the annual consolidated financial statements for the year ended 31 December 2024.

(b) Historical cost convention

The condensed consolidated interim financial statements are prepared under the historical cost convention, except as explained in the relevant accounting policy in the annual consolidated financial statements for the year ended 31 December 2024.

(c) Functional and presentation currency

Items included in the financial statements of the Group are measured using the currency of the primary economic environment in which the Group operates (the 'functional currency'). The condensed consolidated interim financial statements are presented in "Saudi Riyals", which is the Company's functional currency as well.

(d) New standards and amendment to standards and interpretation

The Group has applied the following amendment to standards for the first time for their annual reporting periods commencing on or after 1 January 2025:

- Amendments to IAS 21 'Foreign currencies' ("IAS 21") - Lack of Exchangeability.

The application of the amendment had no significant impact on the Group's condensed consolidated interim financial statements.

2 Material accounting policy information (continued)

2.1 Basis of preparation (continued)

(e) Standards issued but not yet effective

Certain new accounting standards, amendments to accounting standards and interpretations have been published that are not mandatory for 30 September 2025 reporting period and have not been early adopted by the Group.

- Classification and measurement of financial instruments - (Amendments to IFRS 9 and IFRS 7);
- Subsidiaries without Public Accountability: Disclosures (IFRS 19), effective for annual periods beginning on or after 1 January 2027; and
- Presentation and Disclosure in Financial Statements (IFRS 18), effective for annual periods beginning on or after 1 January 2027.

Management is in the process of assessing the impact of such new standards and interpretations on its condensed consolidated interim financial statements.

3 Fair value of assets and liabilities

Fair value is the price that would be received to sell an asset or paid to transfer a liability in an ordinary transaction between market participants at the measurement date in the principal or, in its absence, the most advantageous market to which the Group has access at that date. The fair value of a liability reflects its non-performance risk.

As at 30 September 2025 and 31 December 2024, the fair values of the Group's financial instruments are estimated to approximate their carrying values since the financial instruments are short-term in nature, carry interest rates which are based on prevailing market interest rates and are expected to be realised at their current carrying values within twelve months from the date of condensed consolidated interim statement of financial position.

4 Critical accounting estimates and judgements

The preparation of condensed consolidated interim financial statements requires the use of certain critical estimates and judgments that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the reporting date and the reported amounts of revenues and expenses during the reporting period. Estimates and judgements are continually evaluated and are based on historical experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances. The Group makes estimates and judgements concerning the future. The resulting accounting estimates will, by definition, seldom equal the related actual results. There are no significant changes in critical accounting estimates and judgements used by management in the preparation of the condensed consolidated interim financial statements from those that were applied and disclosed in the annual consolidated financial statements for the year ended 31 December 2024.

(All amounts in Saudi Riyals thousands unless otherwise stated)

4 Critical accounting estimates and judgements (continued)

Impairment of investments accounted for using the equity method (Critical estimate)

At each reporting date, the Group tests the carrying amount of each of its investments accounted for using the equity method for impairment whenever events or changes in circumstances indicate that the carrying amount of such investments may not be recoverable.

When one or more impairment triggers are identified, management estimates the recoverable amount - being the higher of value-in-use and fair value less costs of disposal - for each individual investment accounted for using the equity method ("Investment"). Recoverable amounts, in the case of value-in-use, comprise the Group's share of the discounted cash flows expected to be generated from the respective Investment's underlying assets as reduced by the fair value of outstanding debt of the respective Investment at the measurement date. Such an estimate is based on the management's view of key inputs around future business growth in the forecasted period as well as external market conditions such as future product prices as set out in the approved business plan of the respective investment. It also requires management to make estimates of future business growth rates and to determine the most appropriate discount rate.

The key assumptions used to determine the recoverable amount for the investment, where the management identified impairment indicators as at 30 September 2025, are disclosed and further explained in Note 7.

5 Non-controlling interest

Financial information of subsidiary that has non-controlling interest is provided below:

Proportion of equity interest held by non-controlling interest:

	Country of incorporation	30 September 2025	31 December 2024
Bioprotein Company	Kingdom of Saudi Arabia	**20%**	-

The summarised information of this subsidiary is provided below:

	30 September 2025
Current assets	
Cash and cash equivalents	**32,625**
Other current assets	**-**
Total current assets	**32,625**
Non-current assets	**23,795**
Current liabilities	
Financial liabilities (excluding trade payables)	**(23,795)**
Other current liabilities	**-**
Total current liabilities	**(23,795)**
Net assets	**32,625**

(All amounts in Saudi Riyals thousands unless otherwise stated)

6 Property and equipment

	1 January	Additions	30 September
2025			
Cost			
Leasehold improvements	2,541	-	**2,541**
Furniture and office equipment	1,761	35	**1,796**
Vehicles	3,256	-	**3,256**
Capital work-in-progress	-	24,302	**24,302**
	7,558	24,337	**31,895**
Accumulated depreciation			
Leasehold improvements	(2,541)	-	**(2,541)**
Furniture and office equipment	(1,429)	(96)	**(1,525)**
Vehicles	(1,816)	(469)	**(2,285)**
	(5,786)	(565)	**(6,351)**
Net book value	1,772		**25,544**

	1 January	Additions	31 December
2024			
Cost			
Leasehold improvements	2,541	-	2,541
Furniture and office equipment	1,690	71	1,761
Vehicles	2,718	538	3,256
	6,949	609	7,558
Accumulated depreciation			
Leasehold improvements	(2,537)	(4)	(2,541)
Furniture and office equipment	(1,292)	(137)	(1,429)
Vehicles	(1,341)	(475)	(1,816)
	(5,170)	(616)	(5,786)
Net book value	1,779		1,772

a) Depreciation is charged to the condensed consolidated interim statement of profit or loss using the following depreciation rates:

	Number of years
Leasehold improvements	3 - 5
Furniture and office equipment	3 – 5
Vehicles	4

b) Capital work-in-progress primarily represents cost incurred in relation to the design and blueprint of the plant being set up by Bioprotein Company which is expected to be completed by second half of 2028.

c) Depreciation expense for the period is allocated to general and administrative expenses.

(All amounts in Saudi Riyals thousands unless otherwise stated)

7 Investments accounted for using the equity method

	Note	**30 September 2025 (Unaudited)**	**31 December 2024 (Audited)**
Investments in joint ventures	7.1	**7,941,261**	8,080,689
Investment in an associate	7.2	**233,893**	249,280
		8,175,154	8,329,969

Share of net profit (loss) of investments accounted for using the equity method

		For the three-month period ended 30 September		**For the nine-month period ended 30 September**	
	Note	**2025 (Unaudited)**	**2024 (Unaudited)**	**2025 (Unaudited)**	**2024 (Unaudited)**
Joint ventures	7.1	**27,181**	134,535	**102,777**	272,517
Associate	7.2	**(2,868)**	(8,208)	**(15,387)**	(21,676)
		24,313	126,327	**87,390**	250,841

(All amounts in Saudi Riyals thousands unless otherwise stated)

7 Investments accounted for using the equity method (continued)

7.1 Investments in joint ventures accounted for using the equity method

The Group has investments in the following joint venture limited liability companies:

	Country of incorporation	Effective ownership percentage at	
		30 September 2025	**31 December 2024**
Saudi Chevron Phillips Company ("SCP")	Kingdom of Saudi Arabia	**50%**	50%
Jubail Chevron Phillips Company ("JCP")	Kingdom of Saudi Arabia	**50%**	50%
Aromatics Distribution Company FZCO (a free zone limited liability company) ("ADCO")	United Arab Emirates	**50%**	50%
Saudi Polymers Company (a limited liability company) ("SPCo")	Kingdom of Saudi Arabia	**65%**	65%
Gulf Polymers Distribution Company FZCO (a free zone limited liability company) ("GPDC")	United Arab Emirates	**65%**	65%

a) SCP is principally engaged in the production of liquid fuels, basic organic chemicals, primary gases and gaseous fuels. SCP is a limited liability company registered in Jubail, Kingdom of Saudi Arabia under CR number 2055003839 dated 22 Safar 1417H (corresponding to 8 July 1996) with a branch in Jubail under CR number 2055009584.

b) JCP is principally engaged in the production of basic organic chemicals, propylene and liquid fuels. JCP is a limited liability company registered in Jubail, Kingdom of Saudi Arabia under CR number 2055005901 dated 25 Jumada' II 1424H (corresponding to 23 August 2003).

During 2018, the shareholders of JCP resolved to decrease the share capital of JCP by Saudi Riyals 994 million through their resolution dated 4 September 2018 (corresponding to 24 Dhul Hijjah 1439H). The legal formalities in relation to this matter were completed during 2020. The reduction in share capital is payable on demand to the shareholders of JCP, dependent on its financial capabilities, and is treated as a current liability in JCP's financial statements (also see Note 8).

c) ADCO is principally engaged to distribute the aromatic products (styrene, cyclohexane, propane and benzene) produced by JCP and SCP. ADCO is registered in Dubai Airport Free Zone ("DAFZA"), United Arab Emirates under license number 4105.

d) SPCo is a limited liability company registered in Jubail, Saudi Arabia under CR number 2055008886 dated 29 Dhul-Qadah 1428H (corresponding to 9 December 2007), with a branch in Jubail under Commercial Registration number 2055009065. The principal activities of SPCo are to produce and sell motor fuel blend stock, fuel oil, ethylene, propylene, 1-Hexene, high density and low-density polyethylene and polypropylene. SPCo is a joint venture between Petrochem and Arabian Chevron Phillips Petrochemical Company Limited ("ACPPCL").

During 2019, the shareholders of SPCo resolved to decrease the share capital of SPCo from Saudi Riyals 4.8 billion to Saudi Riyals 1.4 billion. The legal formalities in relation to this matter were completed during the year ended 31 December 2021. The balance of reduction in share capital is payable on demand, dependent on its financial capabilities, and is treated as a current liability in SPCo's financial statements (also see Note 8).

e) GPDC was formed in the Dubai Airport Free Zone on 15 February 2011 as per DAFZA trade license number 1993. The registered address of GPDC is DFZA, Office No.6EA 420, Dubai, United Arab Emirates. The principal activity of GPDC is trading of petrochemicals. GPDC is a distributor for SPCo and is a joint venture of Petrochem and ACPPCL. GPDC has a branch registered with the Government of Dubai under license number 1352664 granted on 8 May 2024. The registered address of the Branch is Office 201, Algiazi Plaza, Algharoud, Dubai.

(All amounts in Saudi Riyals thousands unless otherwise stated)

7 Investments accounted for using the equity method (continued)

7.1 Investments in joint ventures accounted for using the equity method (continued)

Movement in the carrying amount of investments in joint ventures is as follows:

	For the nine-month period ended 30 September 2025					
	SCP	**JCP**	**ADCO**	**SPCo**	**GPDC**	**Total**
1 January 2025	598,318	376,842	61,996	6,693,194	350,339	**8,080,689**
Share of net profit (loss)	(17,266)	20,174	20,706	59,292	19,871	**102,777**
Dividends received from joint venture	-	-	-	-	(268,125)	**(268,125)**
Zakat reimbursed to joint ventures	4,981	-	-	20,939	-	**25,920**
30 September 2025	**586,033**	**397,016**	**82,702**	**6,773,425**	**102,085**	**7,941,261**

	For the nine-month period ended 30 September 2024					
	SCP	**JCP**	**ADCO**	**SPCo**	**GPDC**	**Total**
1 January 2024	866,497	499,573	32,107	6,682,316	674,171	8,754,664
Share of net profit (loss)	179,053	(66,731)	22,113	61,141	76,941	272,517
Dividends received from joint ventures	(262,500)	-	-	-	(146,250)	(408,750)
Zakat reimbursed to joint ventures	7,880	523	-	992	-	9,395
30 September 2024	790,930	433,365	54,220	6,744,449	604,862	8,627,826

The financial performance of the joint ventures was affected during the three-month and nine-month periods ended 30 September 2025 mainly due to a decline in the selling prices of the joint ventures products and an increase in the prices of certain feedstocks. The Group management believes that the decline in selling prices is short term and is expected to improve in the next twelve months.

Impairment assessment for investments in SCP, JCP and SPCo

The performance of SCP, JCP and SPCo was lower than approved budgets for the nine-month period ended 30 September 2025, which represents an impairment indicator for the Company's investments in SCP, JCP and SPCo. An impairment assessment was performed as at 30 September 2025 and no impairment loss was identified.

The estimated value in use for the Company's investments in SCP, JCP and SPCo is most sensitive to the management's assumptions used for the selling prices. If the forecasted selling prices used to determine the value in use of the Company's investments in SCP, JCP and SPCo had been 0.82%, 2.59% and 2.16%, respectively, lower than management's estimates across the forecast period with all other variables remaining constant, the value in use of the Company's investments in SCP, JCP and SPCo will equal to its carrying value. A further decrease in the selling prices would result in an impairment loss in the Company's investments in SCP, JCP and SPCo, respectively.

Pre-zakat discount rates of 9.38%, 9.39% and 9.24% were used in the impairment assessment for Company's investments in SCP, JCP and SPCo, respectively. A reasonable upward change of 0.5% would result in an impairment for the Company's investment in SPCo.

A reasonable change in the other assumptions used in the estimation of the value in use of the Company's investment in SCP, JCP and SPCo is not expected to result in a material impairment loss.

(All amounts in Saudi Riyals thousands unless otherwise stated)

7 Investments accounted for using the equity method (continued)

7.1 Investments in joint ventures accounted for using the equity method (continued)

Summarised financial information for joint ventures is provided below. The information disclosed reflects the amounts presented in the financial statements of the joint ventures and not the Company's share of those amounts.

Summarised statement of financial position

	SCP		**JCP**	
	30 September 2025	**31 December 2024**	**30 September 2025***	**31 December 2024***
Current assets				
Cash and cash equivalents	**144,377**	183,428	**113,081**	49,710
Other current assets	**1,337,714**	1,388,216	**899,165**	764,501
Total current assets	**1,482,091**	1,571,644	**1,012,246**	814,211
Non-current assets	**1,126,427**	1,062,701	**1,207,781**	1,421,085
Current liabilities				
Financial liabilities (excluding trade payables)	**(819,743)**	(812,209)	**(854,543)**	(948,934)
Other current liabilities	**(188,899)**	(268,610)	**(351,178)**	(315,624)
Total current liabilities	**(1,008,642)**	(1,080,819)	**(1,205,721)**	(1,264,558)
Non-current liabilities				
Financial liabilities (excluding trade payables)	**(40,667)**	(3,679)	**(22,676)**	(24,011)
Other non-current liabilities	**(243,955)**	(217,146)	**(108,775)**	(93,880)
Total non-current liabilities	**(284,622)**	(220,825)	**(131,451)**	(117,891)
Net assets	**1,315,254**	1,332,701	**882,855**	852,847

* As at 30 September 2025, JCP's current liabilities exceeded its current assets by Saudi Riyals 193.5 million (31 December 2024: Saudi Riyals 450.3 million) which is primarily due to amounts payable to its shareholders resulting from the reduction in share capital balance. The shareholders of JCP have confirmed that the repayment of such balance will be required after considering the liquidity position of JCP.

SAUDI INDUSTRIAL INVESTMENT GROUP COMPANY
(A Saudi Joint Stock Company)
Notes to the condensed consolidated interim financial statements (Unaudited)
For the three-month and nine-month periods ended 30 September 2025
(All amounts in Saudi Riyals thousands unless otherwise stated)

7 Investments accounted for using the equity method (continued)

7.1 Investments in joint ventures accounted for using the equity method (continued)

Summarised statement of financial position

	ADCO		SPCo	
	30 September 2025	**31 December 2024**	**30 September 2025**	**31 December 2024**
Current assets				
Cash and cash equivalents	**117,738**	101,036	**233,229**	152,089
Other current assets	**393,889**	471,780	**2,251,619**	2,108,918
Total current assets	**511,627**	572,816	**2,484,848**	2,261,007
Non-current assets	**25**	98	**10,295,879**	10,842,754
Current liabilities				
Financial liabilities (excluding trade payables)	**(342,143)**	(443,014)	**(1,312,489)**	(1,668,832)
Other current liabilities	**(4,058)**	(5,876)	**(458,592)**	(586,348)
Total current liabilities	**(346,201)**	(448,890)	**(1,771,081)**	(2,255,180)
Non-current liabilities				
Financial liabilities (excluding trade payables)	**-**	-	**(133,882)**	(98,205)
Other non-current liabilities	**(157)**	(143)	**(571,002)**	(551,890)
Total non-current liabilities	**(157)**	(143)	**(704,884)**	(650,095)
Net assets	**165,294**	123,881	**10,304,762**	10,198,486

Summarised statement of financial position

	GPDC	
	30 September 2025	**31 December 2024**
Current assets		
Cash and cash equivalents	**102,702**	258,178
Other current assets	**114,748**	377,644
Total current assets	**217,450**	635,822
Non-current assets	**25**	170
Current liabilities		
Financial liabilities (excluding trade payables)	**(58,194)**	(92,003)
Other current liabilities	**(628)**	(3,609)
Total current liabilities	**(58,822)**	(95,612)
Non-current liabilities		
Financial liabilities (excluding trade payables)	**-**	-
Other non-current liabilities	**(1,859)**	(1,659)
Total non-current liabilities	**(1,859)**	(1,659)
Net assets	**156,794**	538,721

(All amounts in Saudi Riyals thousands unless otherwise stated)

7 Investments accounted for using the equity method (continued)

7.1 Investments in joint ventures accounted for using the equity method (continued)

The reconciliation of the Group's interest in the joint ventures is as given below:

	SCP		**JCP**	
	30 September 2025	**31 December 2024**	**30 September 2025**	**31 December 2024**
Joint venture net assets	**1,315,254**	1,332,701	**882,855**	852,847
Group's share	**50%**	50%	**50%**	50%
	657,627	666,351	**441,428**	426,424
Intra-group eliminations	**(1,904)**	(6,137)	**-**	-
Cumulative excess of zakat over income tax expense	**(69,690)**	(61,896)	**(44,412)**	(49,582)
Carrying value of investments	**586,033**	598,318	**397,016**	376,842

	ADCO		**SPCo**	
	30 September 2025	**31 December 2024**	**30 September 2025**	**31 December 2024**
Joint venture net assets	**165,294**	123,881	**10,304,762**	10,198,486
Group's share	**50%**	50%	**65%**	65%
	82,647	61,941	**6,698,096**	6,629,016
Intra-group eliminations	**-**	-	**(531)**	(411)
Cumulative deficit of zakat over income tax expense	**55**	55	**75,860**	64,589
Carrying value of investments	**82,702**	61,996	**6,773,425**	6,693,194

	GPDC	
	30 September 2025	**31 December 2024**
Joint venture net assets	**156,794**	538,721
Group's share	**65%**	65%
	101,916	350,169
Intra-group eliminations	**-**	-
Cumulative deficit of zakat over income tax expense	**169**	170
Carrying value of investments	**102,085**	350,339

(All amounts in Saudi Riyals thousands unless otherwise stated)

7 Investments accounted for using the equity method (continued)

7.1 Investments in joint ventures accounted for using the equity method (continued)

Summarised statement of profit or loss and other comprehensive income

	SCP			
	For the three-month period ended 30 September		For the nine-month period ended 30 September	
	2025	**2024**	**2025**	**2024**
Revenue from contracts with customers	**1,039,066**	1,392,544	**3,254,082**	3,549,147
Finance income	**1,982**	4,923	**6,753**	17,687
Depreciation	**(52,820)**	(48,516)	**(149,858)**	(124,196)
Finance costs	**(1,554)**	(40)	**(2,220)**	(162)
Zakat and income tax credit (expense)	**5,671**	(12,988)	**(3,873)**	(46,351)
Profit (loss) for the period	**(12,457)**	92,471	**(47,377)**	329,503
Other comprehensive income for the period	**-**	-	**-**	-
Total comprehensive income (loss) for the period	**(12,457)**	92,471	**(47,377)**	329,503

Summarised statement of profit or loss and other comprehensive income

	JCP			
	For the three-month period ended 30 September		For the nine-month period ended 30 September	
	2025	**2024**	**2025**	**2024**
Revenue from contracts with customers	**1,525,500**	1,611,611	**4,370,289**	4,091,423
Finance income	**1,384**	2,268	**3,193**	4,766
Depreciation	**(78,174)**	(85,052)	**(240,769)**	(249,583)
Finance costs	**(593)**	(1,257)	**(4,961)**	(3,237)
Zakat and income tax credit (expense)	**4,599**	(3,144)	**859**	6,273
Profit (loss) for the period	**(56,617)**	45	**30,009**	(116,993)
Other comprehensive income for the period	**-**	-	**-**	-
Total comprehensive income (loss) for the period	**(56,617)**	45	**30,009**	(116,993)

Summarised statement of profit or loss and other comprehensive income

	ADCO			
	For the three-month period ended 30 September		For the nine-month period ended 30 September	
	2025	**2024**	**2025**	**2024**
Revenue from contracts with customers	**707,374**	1,037,421	**2,342,921**	2,538,469
Depreciation	**-**	(21)	**(49)**	(71)
Finance costs	**-**	(2)	**-**	(4)
Income tax expense	**(1,245)**	(4,336)	**(4,058)**	(4,336)
Profit for the period	**12,591**	15,660	**41,412**	44,219
Other comprehensive income for the period	**-**	-		-
Total comprehensive income for the period	**12,591**	15,660	**41,412**	44,219

(All amounts in Saudi Riyals thousands unless otherwise stated)

7 Investments accounted for using the equity method (continued)

7.1 Investments in joint ventures accounted for using the equity method (continued)

Summarised statement of profit or loss and other comprehensive income

	SPCo			
	For the three-month period ended 30 September		For the nine-month period ended 30 September	
	2025	2024	2025	2024
Revenue from contracts with customers	**1,598,446**	1,679,796	**4,822,684**	4,584,731
Finance income	**2,821**	4,726	**7,235**	10,271
Depreciation	**(228,966)**	(234,901)	**(698,047)**	(703,043)
Finance costs	**(2,436)**	(647)	**(14,231)**	(2,323)
Zakat and income tax expense	**(7,917)**	(11,587)	**(27,433)**	(18,733)
Profit for the period	**70,575**	84,189	**70,522**	125,360
Other comprehensive income for the period	**-**	-	**-**	-
Total comprehensive income for the period	**70,575**	84,189	**70,522**	125,360

Summarised statement of profit or loss and other comprehensive income

	GPDC			
	For the three-month period ended 30 September		For the nine-month period ended 30 September	
	2025	2024	2025	2024
Revenue from contracts with customers	**252,867**	1,523,299	**720,479**	4,292,915
Finance income	**1,816**	3,048	**11,941**	7,661
Depreciation	**(26)**	(216)	**(75)**	(648)
Finance costs	**-**	(1)	**-**	(3)
Income tax expense	**(113)**	-	**(289)**	-
Profit for the period	**7,661**	32,677	**30,573**	118,371
Other comprehensive income for the period	**-**	-	**-**	-
Total comprehensive income for the period	**7,661**	32,677	**30,573**	118,371

The joint ventures' commitments with respect to bank guarantees and approved capital expenditures are as follows:

	30 September 2025	31 December 2024
Bank guarantees		
SCP	**624,020**	632,051
JCP	**1,214,190**	1,074,099
SPCo	**188,350**	312,515
GPDC	**1,214**	9,077
Capital commitments		
SCP	**221,278**	230,655
JCP	**45,301**	61,661
SPCo	**126,571**	230,655

(All amounts in Saudi Riyals thousands unless otherwise stated)

7 Investments accounted for using the equity method (continued)

7.2 Investment in an associate accounted for using the equity method

The Group has an investment in the following associate:

	Country of incorporation	Effective ownership percentage at 30 September 2025	Effective ownership percentage at 31 December 2024
Unibio	England and Wales	**24%**	24%

Unibio is a public company limited by shares, unlisted and incorporated in England and Wales under the Companies Act 2006. Principally, Unibio is a holding company having investments in associates primarily engaged in the bioprotein sector.

Movement in the carrying amount of investment in an associate is as follows:

	For the nine-month period ended 30 September 2025	2024
1 January	**249,280**	271,818
Share of net loss from an associate accounted for using the equity method	**(15,387)**	(21,676)
30 September	**233,893**	250,142

Summarised statement of financial position

	Unibio 30 September 2025	Unibio 31 December 2024
Current assets		
Cash and cash equivalents	**138,655**	188,967
Other current assets	**15,978**	11,183
Total current assets	**154,633**	200,150
Non-current assets	**23,172**	41,141
Current liabilities		
Financial liabilities (excluding trade payables)	**(4,933)**	(9,011)
Other current liabilities	**(2,473)**	(3,321)
Total current liabilities	**(7,406)**	(12,332)
Non-current liabilities		
Financial liabilities (excluding trade payables)	**(1,355)**	(22,642)
Other non-current liabilities	**(1,134)**	-
Total non-current liabilities	**(2,489)**	(22,642)
Net assets	**167,910**	206,317

(All amounts in Saudi Riyals thousands unless otherwise stated)

7 Investments accounted for using the equity method (continued)

7.2 Investment in an associate accounted for using the equity method (continued)

The reconciliation of the Group's interest in the associate is as given below:

	Unibio	
	30 September 2025	**31 December 2024**
Associate net assets	**167,910**	206,317
Group's share	**24%**	24%
	40,299	49,516
Intangible assets - net of amortisation	**193,594**	199,764
Carrying value of investment	**233,893**	249,280

Summarised statement of profit or loss and other comprehensive income

	Unibio			
	For the three-month period ended 30 September		**For the nine-month period ended 30 September**	
	2025	**2024**	**2025**	**2024**
Finance (costs) income	**3,633**	(8,211)	**(5,283)**	(1,481)
Profit (loss) for the period	**1,264**	(19,487)	**(34,612)**	(43,081)
Other comprehensive income for the period	**-**	-	**-**	-
Total comprehensive income (loss) for the period	**1,264**	(19,487)	**(34,612)**	(43,081)

(All amounts in Saudi Riyals thousands unless otherwise stated)

8 Related party transactions and balances

The Group has transactions with its joint ventures and an associate entity.

Related parties comprise the joint ventures, associate entity, directors and key management personnel.

(a) Following are the significant transactions entered into by the Group:

Related parties	**Nature of transactions**	**For the nine-month period ended 30 September 2025**	**2024**
Joint ventures:			
Saudi Chevron Phillips Company	*Dividends received*	**-**	262,500
	Zakat reimbursed to joint ventures	**(4,981)**	(7,880)
Jubail Chevron Phillips Company	*Zakat reimbursed to joint ventures*	**-**	(523)
Saudi Polymers Company	*Zakat reimbursed to joint ventures*	**(20,939)**	(992)
	Reduction of share capital of joint ventures	**170,625**	97,500
Gulf Polymers Distribution Company FZCO	*Dividends received*	**268,125**	146,250
Associate:			
Unibio	*Reimbursement of expenses paid on behalf of the Group*	**(2,375)**	-
Subsidiary of an associate:			
Unibio KSA Aps	*Reimbursement of expenses paid on behalf of the Group*	**(3,376)**	-

(b) Due from related parties

	30 September 2025	**31 December 2024**
Joint ventures:		
SPCo	**475,826**	646,451
JCP	**159,126**	159,126
	634,952	805,577

Outstanding balances represents receivable from joint ventures on account of reduction of their share capital and repayable on demand (Refer Note 7.1 (b) and (d)). Such balances do not bear any financial charges. The group uses a general approach to measure the expected credit loss on the due from related parties balance. The group has considered the liquidity position, past repayment status and the forecast profitability of the joint ventures and the credit risk was assessed low or minimal. No impairment provision was required because the credit risk on these related parties balances was considered minimal.

(All amounts in Saudi Riyals thousands unless otherwise stated)

8 Related party transactions and balances (continued)

(c) Due to related parties

	30 September 2025	31 December 2024
Unibio KSA Aps	**3,376**	-
Unibio	**2,375**	-
	5,751	-

(d) Key management personnel compensation

	For the three-month period ended 30 September		For the nine-month period ended 30 September	
	2025	**2024**	**2025**	**2024**
Salaries and other short-term employee benefits	**2,130**	3,442	**10,136**	10,809
Employee benefit obligations	**266**	257	**798**	772
	2,396	3,699	**10,934**	11,581

Key management personnel represent board members, directors and key personnel of the Group.

9 Cash and cash equivalents

	30 September 2025	31 December 2024
Cash at banks	**84,621**	42,271
Cash in hand	**80**	80
Murabaha deposits	**223,316**	876,717
	308,017	919,068

Murabaha deposits are placed with commercial banks, with a maturity period of three-months or less from date of placement, and yield finance income at commercial rates ranging from 5.60% to 5.70% per annum (31 December 2024: 5.40% to 5.70% per annum).

10 Share capital

As at 30 September 2025, the authorised, issued and fully paid-up share capital comprised 679.3 million ordinary shares (31 December 2024: 754.8 million ordinary shares) of Saudi Riyals 10 per share.

During the year ended 31 December 2024, the Board of Directors' of the Company recommended to decrease the share capital of the Company from Saudi Riyals 7.5 billion to Saudi Riyals 6.8 billion. The legal formalities and approval by shareholders in relation to this matter were completed during the period ended 30 September 2025.

The reduction involved cancellation of 75.5 million ordinary shares with a par value of Saudi Riyals 10 per share and return of capital to shareholders amounting to Saudi Riyals 754.8 million, representing 10.0% of the issued share capital. The cancellation was carried out as the capital was considered in excess of the Company's current and foreseeable operational requirements, considering the Company's objective of optimising the capital structure and improving return on equity.

(All amounts in Saudi Riyals thousands unless otherwise stated)

11 Treasury shares

During the period ended 30 September 2025, the shareholders of the Company approved the Board of Directors' recommendation to purchase a maximum of 11 million shares as follows:

- 10.0 million shares to be held as treasury shares as the Board considers that the Company's market share price is below its fair value; and
- 1.0 million shares to be allocated to the employees' long-term employee incentives program.

During the period ended 30 September 2025, the Company acquired 11 million shares amounting to Saudi Riyals 200.1 million at prevailing market prices and are holding them as treasury shares as at 30 September 2025. The above buy-back was funded by the Company's own resources.

Treasury shares are recognised as a deduction from equity at the amount of consideration paid by the Company for their acquisition, including any directly attributable transaction costs incurred.

12 Zakat

The Group is subject to zakat in accordance with the regulation of the Zakat, Tax and Customs Authority (the "ZATCA"). Provisions for zakat are charged to the condensed consolidated interim statement of profit or loss and other comprehensive income.

The Group's management believes that the existing provisions in the condensed consolidated interim statement of financial position are adequate to cover any additional zakat liabilities that may arise from the ZATCA.

12.1 Provision for zakat

	30 September 2025	**31 December 2024**
1 January	**195,307**	305,438
Provision for the period/year	**14,957**	41,331
Reversal during the period/year (Note 12.2)	**-**	(98,947)
Payments	**(56,113)**	(52,515)
30 September/31 December	**154,151**	195,307

12 Zakat (Continued)

12.2 Status of assessments

(a) Status of assessments of the Company

The Company has filed its zakat return with the ZATCA up to 2024. The Company has finalised its zakat status with the ZATCA for all years up to 31 December 2020 on a standalone basis.

(b) Status of assessments of Petrochem

Petrochem has filed its zakat return with the ZATCA up to 2024. Petrochem has finalised its zakat status with the ZATCA for all years up to 31 December 2020 on a standalone basis. A number of additional assessments have been issued by ZATCA which are as follows:

ZATCA raised additional zakat assessments for the years from 2014 to 2016 amounting to Saudi Riyals 204.2 million. Petrochem filed an appeal against such assessments with ZATCA, following which the case was escalated to General Secretariat of Zakat, tax and Customs Committee ("GSTC"). During the year ended 31 December 2021, the Committee for Resolution of Tax Violations and Disputes ("CRTVD", the first level of GSTC) issued its ruling, accepting Petrochem's appealed items partially and, accordingly, the assessments for such years were reduced to Saudi Riyals 92.5 million. Petrochem and ZATCA, both, had filed an appeal to the Appellate Committee for Tax Violations and Disputes Resolution ("ACTVD", the final level of GSTC). During 2022, ACTVD issued its decision accepting Petrochem's appealed items partially and returning one of the appeal's clauses to CRTVD to consider it again. Accordingly, Petrochem escalated the case to CRTVD again based on the decision of ACTVD. During the year ended 31 December 2024, CRTVD accepted the appeal in the Company's favour. However, ZATCA filed an appeal against the CRTVD ruling with ACTVD. ACTVD has then issued its ruling during the year ended 31 December 2024. During the period ended 30 September 2025, Petrochem has received the final assessment from ZATCA amounting to Saudi Riyals 20.8 million which has been accepted and settled by the Company which was adequately provided by the Company.

13 Segment reporting

The Board of Directors of the Group assesses the financial performance and position of the Group and makes strategic decisions. The Board of Directors has been identified as being the Chief Operating Decision Maker. The Board of Directors uses a measure of group's share of profit/(loss) from joint ventures to assess the performance of the operating segments. In respect of performance appraisal and allocation of resources, the activities and operations of the Group and its joint ventures comprises two operating segments which are within the petrochemical sector. The two operating segments are polymers (representing SPCo and GPDC) and Aromatics (representing SCP, JCP and ADCo).

Refer to Note 7 for information about the performance of these joint ventures.

(All amounts in Saudi Riyals thousands unless otherwise stated)

13 Segment reporting (continued)

Operating assets are located in the Kingdom of Saudi Arabia. The revenue of the operating segments is geographically distributed as follows:

Polymers	For the three-month period ended 30 September		For the nine-month period ended 30 September	
	2025	**2024**	**2025**	**2024**
Domestic/Middle East	**22%**	21%	**21%**	20%
Asia	**36%**	43%	**48%**	47%
Europe/Africa	**42%**	36%	**31%**	33%
	100%	100%	**100%**	100%

Aromatics	For the three-month period ended 30 September		For the nine-month period ended 30 September	
	2025	**2024**	**2025**	**2024**
Domestic/Middle East	**56%**	34%	**51%**	34%
Asia	**22%**	31%	**29%**	33%
Europe/Africa	**22%**	35%	**20%**	33%
	100%	100%	**100%**	100%

14 Basic and diluted earnings per share

Basic earnings per share is calculated by dividing the earnings for the period attributable to the shareholders of the Company by the weighted average number of ordinary shares in issue during the period. As the Company does not have any dilutive potential shares, the diluted earnings per share is the same as the basic earnings per share.

	For the three-month period ended 30 September		For the nine-month period ended 30 September	
	2025	**2024**	**2025**	**2024**
Profit for the period attributable to the shareholders of the Company	**8,333**	98,086	**46,193**	189,985
Weighted average number of ordinary shares used in calculating basic and diluted earnings per share	**672,685**	754,800	**715,624**	754,800
Earnings per share	**0.01**	0.13	**0.06**	0.25